{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T10:36:24Z","timestamp":1793702184813,"version":"4.5.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011946","name":"Abbott Diabetes Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011946","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s13300-025-01816-6","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:02:50Z","timestamp":1762502570000},"page":"73-92","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost\u2013Utility Analysis of FreeStyle Libre Systems in People with Type 2 Diabetes Mellitus on Treatment with Basal Insulin and Poor Glycemic Control in Spain"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7340-2721","authenticated-orcid":false,"given":"Mireya","family":"Robles-Plaza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0106-0091","authenticated-orcid":false,"given":"Fernando","family":"G\u00f3mez-Peralta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8384-043X","authenticated-orcid":false,"given":"Virginia","family":"Bellido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0221-0901","authenticated-orcid":false,"given":"Francisco Javier","family":"Ampudia-Blasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7754-6090","authenticated-orcid":false,"given":"Juana","family":"Carretero-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3710-6370","authenticated-orcid":false,"given":"Ana Mar\u00eda","family":"Cebri\u00e1n-Cuenca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2501-3049","authenticated-orcid":false,"given":"Alberto","family":"de la Cuadra-Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1536-8364","authenticated-orcid":false,"given":"Pedro","family":"Mezquita-Raya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"1816_CR1","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.2337\/dc23-S006","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 6 Glycemic targets: Standards of Care in Diabetes\u20142023. Diabetes Care. 2023;46:S97-110.","journal-title":"Diabetes Care."},{"key":"1816_CR2","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837\u201353.","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"1816_CR3","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854\u201365.","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"1816_CR4","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.2337\/dc23-S007","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 7 Diabetes technology: Standards of Care in Diabetes \u2014 2023. Diabetes Care. 2023;46:S111-27.","journal-title":"Diabetes Care."},{"key":"1816_CR5","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1089\/dia.2021.0007","volume":"23","author":"MA Jackson","year":"2021","unstructured":"Jackson MA, Ahmann A, Shah VN. Type 2 diabetes and the use of real-time continuous glucose monitoring. Diabetes Technol Ther. 2021;23:S27-34.","journal-title":"Diabetes Technol Ther"},{"key":"1816_CR6","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.2337\/dc06-2073","volume":"29","author":"AJ Karter","year":"2006","unstructured":"Karter AJ, Parker MM, Moffet HH, Spence MM, Chan J, Ettner SL, et al. Longitudinal study of new and prevalent use of self-monitoring of blood glucose. Diabetes Care. 2006;29:1757\u201363.","journal-title":"Diabetes Care"},{"key":"1816_CR7","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2337\/dc22-1219","volume":"46","author":"RA Ajjan","year":"2023","unstructured":"Ajjan RA, Heller SR, Everett CC, Vargas-Palacios A, Higham R, Sharples L, et al. Multicenter randomized trial of intermittently scanned continuous glucose monitoring versus self-monitoring of blood glucose in individuals with type 2 diabetes and recent-onset acute myocardial infarction: results of the LIBERATES trial. Diabetes Care. 2023;46:441\u20139.","journal-title":"Diabetes Care"},{"key":"1816_CR8","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/S0140-6736(16)31535-5","volume":"388","author":"J Bolinder","year":"2016","unstructured":"Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kr\u00f6ger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388:2254\u201363.","journal-title":"Lancet"},{"key":"1816_CR9","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s00125-021-05437-z","volume":"64","author":"D Nathanson","year":"2021","unstructured":"Nathanson D, Svensson A-M, Miftaraj M, Franz\u00e9n S, Bolinder J, Eeg-Olofsson K. Effect of flash glucose monitoring in adults with type 1 diabetes: a nationwide, longitudinal observational study of 14,372 flash users compared with 7691 glucose sensor naive controls. Diabetologia. 2021;64:1595\u2013603.","journal-title":"Diabetologia"},{"key":"1816_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s13300-016-0223-6","volume":"8","author":"T Haak","year":"2017","unstructured":"Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline J-P, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8:55\u201373.","journal-title":"Diabetes Ther"},{"key":"1816_CR11","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab013","volume":"5","author":"RM Bergenstal","year":"2021","unstructured":"Bergenstal RM, Kerr MSD, Roberts GJ, Souto D, Nabutovsky Y, Hirsch IB. Flash CGM is associated with reduced diabetes events and hospitalizations in insulin-treated type 2 diabetes. J Endocr Soc. 2021;5:bvab013.","journal-title":"J Endocr Soc"},{"key":"1816_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1089\/dia.2022.0271","volume":"25","author":"B Guerci","year":"2023","unstructured":"Guerci B, Roussel R, Levrat-Guillen F, Detournay B, Vicaut E, De Pouvourville G, et al. Important decrease in hospitalizations for acute diabetes events following FreeStyle Libre system initiation in people with type 2 diabetes on basal insulin therapy in France. Diabetes Technol Ther. 2023;25:20\u201330.","journal-title":"Diabetes Technol Ther"},{"key":"1816_CR13","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 (HAS) Avis sur les dispositifs medicaux. FreeStyle Libre 2. Syst\u00e8me flash d\u2019autosurveillance du glucose. Modification des conditions d\u2019inscription. Adopt\u00e9 par la Commission nationale d\u2019\u00e9valuation des dispositifs m\u00e9dicaux et des technologies de sant\u00e9 le 18 octobre 2022 [Internet]. Saint Denis: HAS; 2022. Available from: https:\/\/www.has-sante.fr\/upload\/docs\/evamed\/CNEDIMTS-6882_FREESTYLE%20LIBRE%202_18%20octobre%202022_(6882)_avis.pdf"},{"key":"1816_CR14","unstructured":"Alparone M, Beduschi A, Bertolasso G, Caruso F, Comazzi G, Fermi A, et al. Deliberazione No XII \/ 1827 seduta del 31\/01\/2024 - Oggetto: Determinazioni in ordine agli indirizzi di programmazione del SSR per l\u2019anno 2024 - (Di concerto con il vicepresidente alparone e gli assessori Lucchini e Fermi) [Internet]. Lombardia: La Giunta Regione Lombardia; Available from: https:\/\/www.snamibs.org\/wp-content\/uploads\/2024\/02\/DELIBERA-N.-XII-1827-DETERMINAZIONI-IN-ORDINE-AGLI-INDIRIZZI-DI-PROGRAMMAZIONE-DEL-SSR-PER-LANNO-2024.pdf"},{"key":"1816_CR15","unstructured":"Volpicelli A. Diabete: novit\u00e0 in Lombardia [Internet]. Farmacia News. 2024 [cited 2024 Nov 21]. Available from: https:\/\/www.farmacianews.it\/diabete-novita-in-lombardia\/"},{"key":"1816_CR16","unstructured":"Direcci\u00f3n General de Cartera de Servicios del SNS y Farmacia. Resoluci\u00f3n de 22 de julio de 2021, de la Direcci\u00f3n General de Cartera Com\u00fan de Servicios del Sistema Nacional de Salud y Farmacia, por la que se hace p\u00fablico el acuerdo de la Comisi\u00f3n de prestaciones, aseguramiento y financiaci\u00f3n de 29 de enero de 2021 sobre los sistemas de monitorizaci\u00f3n continua de glucosa intersticial en tiempo real en la cartera com\u00fan de servicios del Sistema Nacional de Salud. [Internet]. Madrid: Ministerio de Sanidad; 2021. Available from: https:\/\/www.sanidad.gob.es\/profesionales\/prestacionesSanitarias\/CarteraDeServicios\/ContenidoCS\/docs\/Resol_MCG_TR.pdf"},{"key":"1816_CR17","unstructured":"Direcci\u00f3n General de Cartera de Servicios del SNS y Farmacia. Resoluci\u00f3n de 28 de octubre de 2022, de la Direcci\u00f3n General de Cartera Com\u00fan de Servicios del Sistema Nacional de Salud y Farmacia, por la que se hace p\u00fablico el acuerdo de la Comisi\u00f3n de prestaciones, aseguramiento y financiaci\u00f3n de 21 de julio de 2022 en relaci\u00f3n a la priorizaci\u00f3n de pacientes con diabetes mellitus tipo 2 que realicen terapia intensiva con insulina y requieran realizar al menos seis punciones digitales al d\u00eda para la auto-monitorizaci\u00f3n de la glucosa en sangre, a los que facilitar los sistemas de monitorizaci\u00f3n de glucosa [Internet]. Madrid: Ministerio de Sanidad; 2022. Available from: https:\/\/www.sanidad.gob.es\/profesionales\/prestacionesSanitarias\/CarteraDeServicios\/ContenidoCS\/docs\/Resolucion_Priorizacion_Colectivos_DM2.pdf"},{"key":"1816_CR18","unstructured":"Direcci\u00f3n General de Cartera de Servicios del SNS y Farmacia. Resoluci\u00f3n de 7 de abril de 2022, de la Direcci\u00f3n General de Cartera Com\u00fan de Servicios del Sistema Nacional de Salud y Farmacia, por la que se hace p\u00fablico el acuerdo de la Comisi\u00f3n de prestaciones, aseguramiento y financiaci\u00f3n de 21 de octubre de 2021 sobre Sistema de monitorizaci\u00f3n de glucosa mediante sensores (tipo flash) para diabetes mellitus tipo 1 en la infancia y adolescencia en la cartera com\u00fan de servicios del Sistema Nacional de Salud [Internet]. Madrid: Ministerio de Sanidad; 2022. Available from: https:\/\/www.sanidad.gob.es\/profesionales\/prestacionesSanitarias\/CarteraDeServicios\/ContenidoCS\/docs\/Resoluc_DG_EM_Sist_Flash_DM1.pdf"},{"key":"1816_CR19","unstructured":"Direcci\u00f3n General de Cartera de Servicios del SNS y Farmacia. Resoluci\u00f3n de 30 de noviembre de 2020, de la Direcci\u00f3n General de Cartera Com\u00fan de Servicios del Sistema Nacional de Salud y Farmacia, por la que se hace p\u00fablico el acuerdo de la Comisi\u00f3n de prestaciones, aseguramiento y financiaci\u00f3n de 14 de julio de 2020 sobre el sistema de monitorizaci\u00f3n de glucosa mediante sensores (tipo flash) en la cartera com\u00fan de servicios del Sistema Nacional de Salud. [Internet]. Madrid: Ministerio de Sanidad; 2020. Available from: https:\/\/www.sanidad.gob.es\/profesionales\/prestacionesSanitarias\/CarteraDeServicios\/ContenidoCS\/docs\/Resol_Flash_2020.pdf"},{"key":"1816_CR20","unstructured":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Diabetes y Enfermedades Metab\u00f3licas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Sociedad Espa\u00f1ola de Diabetes (SED). Dossier de prensa - Prevalencia de la diabetes en Espa\u00f1a: Estudio Di@bet.es [Internet]. Madrid: CIBERDEM; 2011. Available from: https:\/\/www.ciberdem.org\/media\/434051\/dossier-de-prensa_estudio-diabetes_ciberdem.pdf"},{"key":"1816_CR21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","volume":"402","author":"GBD 2021 Diabetes Collaborators","year":"2023","unstructured":"GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;402:203\u201334.","journal-title":"Lancet"},{"key":"1816_CR22","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.pcd.2021.02.003","volume":"15","author":"M Mata-Cases","year":"2021","unstructured":"Mata-Cases M, Franch-Nadal J, Real J, Vlacho B, G\u00f3mez-Garc\u00eda A, Mauricio D. Evaluation of clinical and antidiabetic treatment characteristics of different sub-groups of patients with type 2 diabetes: data from a Mediterranean population database. Prim Care Diabetes. 2021;15:588\u201395.","journal-title":"Prim Care Diabetes"},{"key":"1816_CR23","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.2337\/dc20-1690","volume":"44","author":"R Roussel","year":"2021","unstructured":"Roussel R, Riveline J-P, Vicaut E, de Pouvourville G, Detournay B, Emery C, et al. Important drop in rate of acute diabetes complications in people with type 1 or type 2 diabetes after initiation of flash glucose monitoring in France: the RELIEF study. Diabetes Care. 2021;44:1368\u201376.","journal-title":"Diabetes Care"},{"key":"1816_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.semerg.2023.102066","volume":"49","author":"JC Aguirre Rodr\u00edguez","year":"2023","unstructured":"Aguirre Rodr\u00edguez JC, S\u00e1nchez Cambronero M, Guisasola C\u00e1rdenas M, Generoso Torres MN, Hidalgo Rodr\u00edguez A, Mart\u00edn Enguix D, et al. [Type 2 diabetes in Andalusia: Resources use and economic cost]. SEMERGEN. 2023;49:102066.","journal-title":"SEMERGEN"},{"key":"1816_CR25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/(SICI)1520-7560(199905\/06)15:3<205::AID-DMRR29>3.0.CO;2-O","volume":"15","author":"RR Rubin","year":"1999","unstructured":"Rubin RR, Peyrot M. Quality of life and diabetes. Diabetes Metab Res Rev. 1999;15:205\u201318.","journal-title":"Diabetes Metab Res Rev"},{"key":"1816_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001330","volume":"8","author":"I Oyag\u00fcez","year":"2020","unstructured":"Oyag\u00fcez I, Merino-Torres JF, Brito M, Bellido V, Cardona-Hernandez R, Gomez-Peralta F, et al. Cost analysis of the flash monitoring system (FreeStyle Libre 2) in adults with type 1 diabetes mellitus. BMJ Open Diabetes Res Care. 2020;8:e001330.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"1816_CR27","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1007\/s13300-021-01064-4","volume":"12","author":"I Oyag\u00fcez","year":"2021","unstructured":"Oyag\u00fcez I, G\u00f3mez-Peralta F, Artola S, Carrasco FJ, Carretero-G\u00f3mez J, Garc\u00eda-Soidan J, et al. Cost analysis of FreeStyle Libre\u00ae 2 system in type 2 diabetes mellitus population. Diabetes Ther. 2021;12:2329\u201342.","journal-title":"Diabetes Ther"},{"key":"1816_CR28","unstructured":"Bellido Casta\u00f1eda V, De la Cuadra-Grande A, Ampudia-Blasco FJ, Carretero Gomez J, Cebri\u00e1n Cuenca A, G\u00f3mez-Peralta F, et al. An\u00e1lisis de costes de los sistemas FreeStyle Libre\u00ae en Espa\u00f1a para adultos con diabetes mellitus tipo 2 en tratamiento con insulina basal y HbA1c >8% [Internet]. Oviedo: 65\u00b0 Congreso de la Sociedad Espa\u00f1ola de Endocrinolog\u00eda y Nutrici\u00f3n (SEEN); 2024. Available from: https:\/\/congresoseen2024.com\/presentacion\/"},{"key":"1816_CR29","doi-asserted-by":"crossref","unstructured":"Carretero Gomez J, Robles-Plaza M, Ampudia-Blasco F, Bellido Casta\u00f1eda V, Cebri\u00e1n Cuenca A, Gomez Peralta F, et al. Impacto De Los Sistemas FreeStyle Libre\u00ae Para La Monitorizaci\u00f3n Gluc\u00e9mica Frente Al Autoan\u00e1lisis De Glucosa Capilar En Personas Con Diabetes Mellitus Tipo 2 En Tratamiento Con Insulina Basal Y HbA1c>8% En Espa\u00f1a [Internet]. Gran Canaria: 45 Congreso Nacional de la Sociedad Espa\u00f1ola de Medicina Interna (SEMI); 2024. Available from: https:\/\/congresosemi.com\/SEMI2024","DOI":"10.1016\/S0014-2565(24)00215-7"},{"issue":"24","key":"1816_CR30","first-page":"00039","volume":"S1098\u20133015","author":"K Szafranski","year":"2024","unstructured":"Szafranski K, De Pouvourville G, Greenberg D, Harris S, Jendle J, Shaw JE, et al. The DEDUCE model, a cost\u2013utility tool using patient-level microsimulation to evaluate sensor-based glucose monitoring systems in type 1 and type 2 diabetes: Comparative validation. Value Health. 2024;S1098\u20133015(24):00039\u201341.","journal-title":"Value Health"},{"key":"1816_CR31","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/S2213-8587(17)30221-8","volume":"5","author":"S Basu","year":"2017","unstructured":"Basu S, Sussman JB, Berkowitz SA, Hayward RA, Yudkin JS. Development and validation of risk equations for complications of type 2 diabetes (RECODe) using individual participant data from randomised trials. Lancet Diabetes Endocrinol. 2017;5:788\u201398.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1816_CR32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force. Value Health. 2022;25:10\u201331.","journal-title":"Value Health"},{"key":"1816_CR33","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12872-018-0914-1","volume":"18","author":"J Navarro-P\u00e9rez","year":"2018","unstructured":"Navarro-P\u00e9rez J, Orozco-Beltran D, Gil-Guillen V, Pallares V, Valls F, Fernandez A, et al. Mortality and cardiovascular disease burden of uncontrolled diabetes in a registry-based cohort: the ESCARVAL-risk study. BMC Cardiovasc Disord. 2018;18:180.","journal-title":"BMC Cardiovasc Disord"},{"key":"1816_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2021-002590","volume":"10","author":"AL Carlson","year":"2022","unstructured":"Carlson AL, Daniel TD, DeSantis A, Jabbour S, Karslioglu French E, Kruger D, et al. Flash glucose monitoring in type 2 diabetes managed with basal insulin in the USA: a retrospective real-world chart review study and meta-analysis. BMJ Open Diabetes Res Care. 2022;10:e002590.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"1816_CR35","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/dom.12406","volume":"17","author":"D D\u2019Alessio","year":"2015","unstructured":"D\u2019Alessio D, H\u00e4ring H-U, Charbonnel B, de Pablos-Velasco P, Candelas C, Dain M-P, et al. Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes. Diabetes Obes Metab. 2015;17:170\u20138.","journal-title":"Diabetes Obes Metab"},{"key":"1816_CR36","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"HC Gerstein","year":"2008","unstructured":"Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545\u201359.","journal-title":"N Engl J Med."},{"key":"1816_CR37","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1111\/dom.12927","volume":"19","author":"D Mauricio","year":"2017","unstructured":"Mauricio D, Meneghini L, Seufert J, Liao L, Wang H, Tong L, et al. Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA. Diabetes Obes Metab. 2017;19:1155\u201364.","journal-title":"Diabetes Obes Metab"},{"key":"1816_CR38","unstructured":"Perestelo P\u00e9rez L, Rivero Santana A, Castilla Rodr\u00edguez I, \u00c1lvarez P\u00e9rez Y, Ramos Garc\u00eda V, Garc\u00eda P\u00e9rez L, et al. Efectividad, seguridad y coste-efectividad de los sistemas de monitorizaci\u00f3n continua de glucosa intersticial en tiempo real (MCG-TR) para la Diabetes Mellitus tipo 1 y 2. Actualizaci\u00f3n. [Internet]. Tenerife: Servicio de Evaluaci\u00f3n del Servicio Canario de Salud (SESCS); 2020. Available from: https:\/\/www3.gobiernodecanarias.org\/sanidad\/scs\/content\/9b7a04b3-6c5f-11eb-80f0-cdea93d4661f\/SESCS_2019_Act_SMCG_TR_NIPO"},{"key":"1816_CR39","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/dom.12689","volume":"18","author":"K Khunti","year":"2016","unstructured":"Khunti K, Alsifri S, Aronson R, Cigrovski Berkovi\u0107 M, Enters-Weijnen C, Fors\u00e9n T, et al. Rates and predictors of hypoglycaemia in 27,585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study. Diabetes Obes Metab. 2016;18:907\u201315.","journal-title":"Diabetes Obes Metab"},{"key":"1816_CR40","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1111\/dme.13355","volume":"34","author":"RJ Barranco","year":"2017","unstructured":"Barranco RJ, Gomez-Peralta F, Abreu C, Delgado-Rodriguez M, Moreno-Carazo A, Romero F, et al. Incidence, recurrence and cost of hyperglycaemic crises requiring emergency treatment in Andalusia, Spain. Diabet Med. 2017;34:966\u201372.","journal-title":"Diabet Med"},{"key":"1816_CR41","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1111\/dme.12843","volume":"32","author":"RJ Barranco","year":"2015","unstructured":"Barranco RJ, Gomez-Peralta F, Abreu C, Delgado M, Palomares R, Romero F, et al. Incidence and care-related costs of severe hypoglycaemia requiring emergency treatment in Andalusia (Spain): the PAUEPAD project. Diabet Med. 2015;32:1520\u20136.","journal-title":"Diabet Med"},{"key":"1816_CR42","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","volume":"362","author":"HN Ginsberg","year":"2010","unstructured":"ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563\u201374.","journal-title":"N Engl J Med."},{"key":"1816_CR43","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","volume":"362","author":"WC Cushman","year":"2010","unstructured":"ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC, Grimm RH, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575\u201385.","journal-title":"N Engl J Med."},{"key":"1816_CR44","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1161\/CIRCOUTCOMES.113.000497","volume":"7","author":"JF Burke","year":"2014","unstructured":"Burke JF, Hayward RA, Nelson JP, Kent DM. Using internally developed risk models to assess heterogeneity in treatment effects in clinical trials. Circ Cardiovasc Qual Outcomes. 2014;7:163\u20139.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"1816_CR45","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/S2213-8587(15)00291-0","volume":"3","author":"Diabetes Prevention Program Research Group","year":"2015","unstructured":"Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015;3:866\u201375.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1816_CR46","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa1212914","volume":"369","author":"RR Wing","year":"2013","unstructured":"Look AHEAD Research Group, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145\u201354.","journal-title":"N Engl J Med."},{"key":"1816_CR47","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.avdiab.2012.01.002","volume":"28","author":"E Men\u00e9ndez Torre","year":"2012","unstructured":"Men\u00e9ndez Torre E, Tart\u00f3n Garc\u00eda T, Ortega Mill\u00e1n C, Fornos P\u00e9rez JA, Garc\u00eda Mayor R, L\u00f3pez Fern\u00e1ndez ML. Recomendaciones 2012 de la Sociedad Espa\u00f1ola de Diabetes sobre la utilizaci\u00f3n de tiras reactivas para la medici\u00f3n de la glucemia capilar en personas con diabetes. Avances en Diabetolog\u00eda. 2012;28:3\u20139.","journal-title":"Avances en Diabetolog\u00eda"},{"key":"1816_CR48","unstructured":"Gonz\u00e1lez Pacheco H, Ramallo Fari\u00f1a Y, Rivero Santana A, Valc\u00e1rcel Nazco C, Toledo Ch\u00e1varri A, Garc\u00eda P\u00e9rez L, et al. Estudio de Monitorizaci\u00f3n: \u201cSistema de Monitorizaic\u00f3n de Glucosa mediante sensores (tipo Flash) para la diabetes mellitus tipo 1 en la infancia y adolescencia\u201d [Internet]. Santa Cruz de Tenerife: Servicio de Evaluaci\u00f3n del Servicio Canario de Salud (SESCS); 2021. Available from: https:\/\/sescs.es\/wp-content\/uploads\/2022\/07\/SESCS_Informe-final-EM_FLASH_DEF_NIPO.pdf?x55084"},{"key":"1816_CR49","doi-asserted-by":"crossref","unstructured":"Parekh W, Hoskins N, Baker-Knight J, Ramirez de Arellano A, Mezquita Raya P. The Economic Burden of Insulin-Related Hypoglycemia in Spain. Diabetes Ther. 2017;8:899\u2013913.","DOI":"10.1007\/s13300-017-0285-0"},{"key":"1816_CR50","doi-asserted-by":"crossref","unstructured":"Orozco-Beltr\u00e1n D, Mezquita-Raya P, Ram\u00edrez de Arellano A, Gal\u00e1n M. Self-reported frequency and impact of hypoglycemic events in Spain. Diabetes Ther. 2014;5:155\u201368.","DOI":"10.1007\/s13300-014-0057-z"},{"key":"1816_CR51","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.endinu.2020.10.007","volume":"68","author":"FJ Ampudia-Blasco","year":"2021","unstructured":"Ampudia-Blasco FJ, Artime E, D\u00edaz S, Rubio M, Reviriego J, Mitchell B, et al. Conversations and reactions around severe hypoglycaemia (CRASH): Spanish results of a global survey of people with type 1 diabetes or insulin-treated type 2 diabetes and caregivers. Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n. 2021;68:557\u201366.","journal-title":"Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n"},{"key":"1816_CR52","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3111\/13696990903336597","volume":"12","author":"M Hammer","year":"2009","unstructured":"Hammer M, Lammert M, Mej\u00edas SM, Kern W, Frier BM. Costs of managing severe hypoglycaemia in three European countries. J Med Econ. 2009;12:281\u201390.","journal-title":"J Med Econ"},{"key":"1816_CR53","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.avdiab.2013.07.007","volume":"29","author":"C Crespo","year":"2013","unstructured":"Crespo C, Brosa M, Soria-Juan A, Lopez-Alba A, L\u00f3pez-Mart\u00ednez N, Soria B. Costes directos de la diabetes mellitus y de sus complicaciones en Espa\u00f1a (Estudio SECCAID: Spain estimated cost Ciberdem-Cabimer in Diabetes). Avances Diabetol. 2013;29:182\u20139.","journal-title":"Avances Diabetol"},{"key":"1816_CR54","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1185\/030079905X65349","volume":"21","author":"JA Ray","year":"2005","unstructured":"Ray JA, Valentine WJ, Secnik K, Oglesby AK, Cordony A, Gordois A, et al. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain. Curr Med Res Opin. 2005;21:1617\u201329.","journal-title":"Curr Med Res Opin"},{"key":"1816_CR55","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.recesp.2013.12.016","volume":"67","author":"JF Delgado","year":"2014","unstructured":"Delgado JF, Oliva J, Llano M, Pascual-Figal D, Grillo JJ, Com\u00edn-Colet J, et al. Costes sanitarios y no sanitarios de personas que padecen insuficiencia cardiaca cr\u00f3nica sintom\u00e1tica en Espa\u00f1a. Rev Esp Cardiol. 2014;67:643\u201350.","journal-title":"Rev Esp Cardiol"},{"key":"1816_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-12-315","volume":"12","author":"J Lopez-Bastida","year":"2012","unstructured":"Lopez-Bastida J, Oliva Moreno J, Worbes Cerezo M, Perestelo Perez L, Serrano-Aguilar P, Mont\u00f3n-\u00c1lvarez F. Social and economic costs and health-related quality of life in stroke survivors in the Canary Islands, Spain. BMC Health Serv Res. 2012;12:315.","journal-title":"BMC Health Serv Res"},{"key":"1816_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.gaceta.2025.102448","volume":"39","author":"M Trapero-Bertran","year":"2025","unstructured":"Trapero-Bertran M, Oliva J, Catal\u00e1-L\u00f3pez F, Garc\u00eda-P\u00e9rez L, Seg\u00fa L, Alegre-del-Rey EJ, et al. Guideline for the economic evaluation of medicines: a proposal by the Spanish National Health System\u2019s Advisory Committee for Pharmaceutical Financing. Gac Sanit. 2025;39:102448.","journal-title":"Gac Sanit"},{"key":"1816_CR58","unstructured":"Instituto Nacional de Estad\u00edstica (INE). \u00cdndice de precios de consumo [Internet]. Madrid: INE; Available from: https:\/\/www.ine.es\/dyngs\/INEbase\/es\/operacion.htm?c=Estadistica_C&cid=1254736176802&menu=ultiDatos&idp=1254735976607"},{"key":"1816_CR59","first-page":"73","volume":"14","author":"SP Bilir","year":"2018","unstructured":"Bilir SP, Hellmund R, Wehler B, Li H, Munakata J, Lamotte M. Cost-effectiveness analysis of a flash glucose monitoring system for patients with type 1 diabetes receiving intensive insulin treatment in Sweden. Eur Endocrinol. 2018;14:73\u20139.","journal-title":"Eur Endocrinol"},{"key":"1816_CR60","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12913-022-07567-5","volume":"22","author":"C Escobar","year":"2022","unstructured":"Escobar C, Morales C, Capel M, Sim\u00f3n S, P\u00e9rez-Alc\u00e1ntara F, Pomares E. Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study. BMC Health Serv Res. 2022;22:217.","journal-title":"BMC Health Serv Res"},{"key":"1816_CR61","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jval.2016.10.007","volume":"20","author":"LS Matza","year":"2017","unstructured":"Matza LS, Stewart KD, Davies EW, Hellmund R, Polonsky WH, Kerr D. Health state utilities associated with glucose monitoring devices. Value Health. 2017;20:507\u201311.","journal-title":"Value Health"},{"key":"1816_CR62","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.vhri.2021.10.005","volume":"30","author":"A Chantzaras","year":"2022","unstructured":"Chantzaras A, Yfantopoulos J. Evaluating the incidence and risk factors associated with mild and severe hypoglycemia in insulin-treated type 2 diabetes. Value Health Reg Issues. 2022;30:9\u201317.","journal-title":"Value Health Reg Issues"},{"key":"1816_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13030642","volume":"13","author":"M Conti","year":"2024","unstructured":"Conti M, Massari G, Meneghini E, Pasquino B, Agosti B, Chinotti F, et al. Effectiveness and safety of the intermittently scanned continuous glucose monitoring system FreeStyle Libre 2 in patients with type 2 diabetes treated with basal insulin or oral antidiabetic drugs: an observational, retrospective real-world study. J Clin Med. 2024;13:642.","journal-title":"J Clin Med"},{"key":"1816_CR64","doi-asserted-by":"publisher","unstructured":"Eeg-Olofsson K, Nathanson D, Spelman T, Kyhlstedt M, Seibold A, Levrat-Guillen F, et al. Severe hypoglycaemia is associated with increased risk of adverse cardiovascular complications in adults with type 1 diabetes: risk mitigation using intermittently scanned continuous glucose monitoring. Diabetologia [Internet]. 2025 [cited 2025 June 17]; Available from: https:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/s00125-025-06438-y","DOI":"10.1007\/s00125-025-06438-y"},{"key":"1816_CR65","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00125-024-06289-z","volume":"68","author":"D Nathanson","year":"2025","unstructured":"Nathanson D, Eeg-Olofsson K, Spelman T, B\u00fclow E, Kyhlstedt M, Levrat-Guillen F, et al. Intermittently scanned continuous glucose monitoring compared with blood glucose monitoring is associated with lower HbA1c and a reduced risk of hospitalisation for diabetes-related complications in adults with type 2 diabetes on insulin therapies. Diabetologia. 2025;68:41\u201351.","journal-title":"Diabetologia"},{"key":"1816_CR66","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/hec.3633","volume":"27","author":"L Vallejo-Torres","year":"2018","unstructured":"Vallejo-Torres L, Garc\u00eda-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Econ. 2018;27:746\u201361.","journal-title":"Health Econ"},{"key":"1816_CR67","doi-asserted-by":"publisher","unstructured":"Vallejo-Torres L. Estimating the Incremental Cost Per QALY Produced by the Spanish NHS: A Fixed-Effect Econometric Approach. PharmacoEconomics [Internet]. 2024 [cited 2024 Nov 4]; Available from: https:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/s40273-024-01441-4","DOI":"10.1007\/s40273-024-01441-4"},{"key":"1816_CR68","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1111\/dom.15703","volume":"26","author":"S Del Prato","year":"2024","unstructured":"Del Prato S, Giorgino F, Szafranski K, Poon Y. Cost\u2013utility analysis of a flash continuous glucose monitoring system in the management of people with type 2 diabetes mellitus on basal insulin therapy\u2014an Italian healthcare system perspective. Diabetes Obes Metab. 2024;26:3633\u201341.","journal-title":"Diabetes Obes Metab"},{"key":"1816_CR69","doi-asserted-by":"publisher","DOI":"10.2337\/db24-1051-P","volume":"73","author":"SB Harris","year":"2024","unstructured":"Harris SB, Cimino S, Thanh Yen Nguyen T, Poon Y, Szafranski K. 1051-P: Cost-effectiveness of flash CGM compared with SMBG\u2014a Canadian private-payer perspective. Diabetes. 2024;73:1051-P.","journal-title":"Diabetes"},{"key":"1816_CR70","doi-asserted-by":"publisher","unstructured":"Karagiannis T, Avgerinos I, Toumpalidou M, Liakos A, Kitsios K, Dimitriadis G, et al. Patients\u2019 and Clinicians\u2019 Preferences on Outcomes and Medication Attributes for Type 2 Diabetes: a Mixed-Methods Study. J GEN INTERN MED [Internet]. 2020 [cited 2024 Oct 31]; Available from: http:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/s11606-019-05608-0","DOI":"10.1007\/s11606-019-05608-0"},{"key":"1816_CR71","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2022-003025","volume":"11","author":"IP Smith","year":"2023","unstructured":"Smith IP, Whichello CL, Veldwijk J, Rutten-van M\u00f6lken MPMH, Groothuis-Oudshoorn CGM, Vos RC, et al. Diabetes patient preferences for glucose-monitoring technologies: results from a discrete choice experiment in Poland and the Netherlands. BMJ Open Diab Res Care. 2023;11:e003025.","journal-title":"BMJ Open Diab Res Care"},{"key":"1816_CR72","first-page":"231","volume":"30","author":"B Varughese","year":"2021","unstructured":"Varughese B, Silvey M, Harper G, Rajkovic I, Hoffmann P. The value of optional alarms in continuous glucose monitoring devices: a survey on patients and their physicians. Diabetes, Stoffwechsel und Herz. 2021;30:231\u201342.","journal-title":"Diabetes, Stoffwechsel und Herz"},{"key":"1816_CR73","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.2337\/dc24-S006","volume":"47","author":"NA ElSayed","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee, ElSayed NA, Aleppo G, Bannuru RR, Bruemmer D, Collins BS, et al. 6 Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes\u20142024. Diabetes Care. 2024;47:S111-25.","journal-title":"Diabetes Care."}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01816-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-025-01816-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01816-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T08:03:29Z","timestamp":1769501009000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-025-01816-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1816"],"URL":"https:\/\/doi.org\/10.1007\/s13300-025-01816-6","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mireya Robles-Plaza and Alberto de la Cuadra-Grande are employees of PORIB, a consultant company specializing in economic evaluation of health care interventions and outcomes research, which received fees for providing methodological support to this project. Fernando G\u00f3mez-Peralta has taken part in advisory panels for Abbott, Insulcloud S.L., Sanofi and Novo Nordisk; has received research support from Sanofi, Novo Nordisk, Boehringer Ingelheim Pharmaceuticals and Lilly; and has acted as a speaker for Abbott, Sanofi, Novo Nordisk, Boehringer Ingelheim Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Co. and Lilly. Virginia Bellido has served as a consultant\/advisor for Abbott Diabetes Care, AstraZeneca, Eli Lilly, Merck, Novo Nordisk, and Sanofi and as a speaker for Abbott Diabetes Care, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, and Sanofi and has received grant support from Abbott Diabetes Care, Eli Lilly, Novo Nordisk and Sanofi. Francisco Javier Ampudia-Blasco has served as a consultant\/advisor for Abbott Diabetes Care, AstraZeneca, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, LifeScan, MannKind Co., Medtronic, Menarini, Merck, Novartis, Novo Nordisk, and Sanofi and as a speaker for Abbott Diabetes Care, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, LifeScan, Eli Lilly, Madaus, Medtronic, Menarini, Merck, Novartis, Novo Nordisk, and Sanofi and has received grant support from Novo Nordisk and Sanofi. Juana Carretero G\u00f3mez reported receiving consulting fees and speaking from AstraZeneca, Boehringer Ingelheim, Lilly, Abbot Diabetes Care and Novo Nordisk. Ana Mar\u00eda Cebri\u00e1n-Cuenca has served as a consultant\/advisor for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Menarini, Merck, Novo Nordisk, and Sanofi and as a speaker for Abbott Diabetes Care, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Eli Lilly, Menarini, Merck, Novartis, Novo Nordisk, and Sanofi and has received grant support from Merck, Novo Nordisk and Sanofi. Pedro Mezquita-Raya has served as a consultant\/advisor on scientific boards for Abbott, AstraZeneca, FAES and Novo Nordisk; as a speaker for AstraZeneca, Eli Lilly, FAES, Fresenius and Novo Nordisk; and in research activities for Eli Lilly & Company and Novo Nordisk. None of the authors received fees for being listed in this manuscript\u2019s authorship.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}